Hims & Hers Health Inc. (HIMS) experienced a pre-market soar of 5.09%, reflecting strong investor sentiment ahead of the company's upcoming earnings report.

The surge is primarily driven by reports of a potential leadership change at the U.S. Food and Drug Administration (FDA), with the President planning to dismiss Commissioner Marty Makary. This is viewed positively as the FDA had previously imposed restrictions on compounded GLP-1 drugs, which impacted Hims & Hers Health's business. A new commissioner could lead to loosened regulatory enforcement, benefiting the company's telehealth and medication distribution model.

Furthermore, market optimism around the company's weight-loss drug partnerships is fueling the rally. Hims & Hers has re-signed its cooperation agreement with Novo Nordisk and entered a new partnership with Eli Lilly in April, significantly expanding its weight-loss drug distribution capabilities as a direct-to-consumer telehealth platform. This expansion aligns with strong demand for GLP-1 medications, as evidenced by Novo Nordisk's robust quarterly sales performance that exceeded expectations.